The software promises up to twice the accuracy and image quality of traditional systems, GE Healthcare said. Faster, more accurate tools can help doctors better assess when a treatment is working, or when they may need to adjust their strategy.
The technology has not yet won CE Marking in the European Union.
"We know that approximately 70% of cancer patients don’t always respond to their initial course of treatment," GE Healthcare MICT president & CEO Steve Gray said in prepared remarks. "If we can give clinicians an accurate, reliable, and faster tool to confirm that a change in treatment is needed, the patient will benefit greatly. For example, PET/CT can help clinicians determine whether chemotherapy is working in fewer cycles, saving patients unnecessary procedures."
The FDA win is more good news for GE, which has recently won nearly $93 million in Pentagon contracts in 2 separate announcements for patient monitoring and for a "digital imaging network-picture archive communication system."